Bone marrow necrosis in acute leukemia: Clinical characteristic and outcomeTalha Badar, Farhad Ravandi, Sherry Pierce et al.|American Journal of Hematology|2015Cited by 39
Phase 1 study of combinatorial sorafenib, <scp>G‐CSF</scp>, and plerixafor treatment in relapsed/refractory, <scp>FLT3‐ITD</scp>‐mutated acute myelogenous leukemia patientsGautam Borthakur, Michael Andreeff, Zhihong Zeng et al.|American Journal of Hematology|2020Cited by 38
Factors associated with risk of central nervous system relapse in patients with non‐core binding factor acute myeloid leukemiaElias Jabbour, Hagop M. Kantarjian, Naval Daver et al.|American Journal of Hematology|2017Cited by 34